The Phase 3 trial compared Roche’s divarasib with treatments sold by Amgen and Bristol Myers in patients with non-small cell lung cancer.
An article from
Dive Brief
The Phase 3 trial compared Roche’s divarasib with treatments sold by Amgen and Bristol Myers in patients with non-small cell lung cancer.
Published July 2, 2026
By
Roche’s lung cancer pill beats rivals in head-to-head Phase 3 study
Roche claims clinical trial success for lung cancer drug
Roche’s Lung Cancer Pill Outperforms Rival Drugs in Late Trial
Genentech’s Divarasib Shows Superiority in Head-to-Head Phase III Trial Against Approved KRAS G12C Inhibitors in Non-Small Cell Lung Cancer
Revolution Medicines shares promising data around KRAS drug combination
Roche drug sets new standard for KRAS-driven lung cancer
Bristol Myers details Krazati confirmatory study failure in colorectal cancer
